Gregoric Igor D, Bruckner Brian A, Jacob Leon, Kar Biswajit, Cohn William E, La Francesca Saverio, Frazier O H
Division of Cardiopulmonary Transplantation, Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, Texas 77225-0345, USA.
Ann Thorac Surg. 2008 May;85(5):1646-9. doi: 10.1016/j.athoracsur.2008.01.020.
Most patients undergoing destination therapy with a HeartMate XVE left ventricular assist device will eventually require pump exchange to continue long-term cardiac support.
To determine whether left ventricular assist device exchange can be accomplished with low morbidity and mortality, we retrospectively reviewed the records of 14 patients who experienced pump malfunction and subsequently required replacement of their HeartMate XVE left ventricular assist devices with HeartMate II axial-flow pumps. We collected data regarding duration of support and reasons for pump failure, perioperative characteristics, and operative approach.
On average, patients were supported 473 +/- 233 days with HeartMate XVE pumps. Seven early patients required both subcostal and sternotomy incisions; 7 later patients had subcostal incisions only. Thirteen patients underwent successful exchange to the HeartMate II; 1 patient died in the operating room. Another patient died in the perioperative period (30-day mortality, 14% [2 of 14]). There were significant differences between the two groups. The patients who required only subcostal incisions had shorter operative times (187 versus 220 minutes; p = 0.04) and required fewer transfused blood products (packed red blood cells, 8.6 versus 28.7 units; p = 0.03; and fresh-frozen plasma, 12.4 versus 30.9 units; p = 0.04). Additionally, the patients with subcostal incisions had shorter postoperative intensive care unit stays (5.3 +/- 1.1 versus 8.4 +/- 3.1 days for redo sternotomy patients; p = 0.03). Of the survivors, average hospital stay was 22 +/- 14 days. Average long-term follow-up was 11.2 +/- 7.8 months; 71% (10 of 14) of patients are currently alive.
Exchange of a HeartMate XVE to a HeartMate II can be accomplished with relatively low morbidity and mortality through a subcostal approach.
大多数接受HeartMate XVE左心室辅助装置目标治疗的患者最终需要更换泵以继续长期心脏支持。
为了确定左心室辅助装置更换能否在低发病率和死亡率的情况下完成,我们回顾性分析了14例经历泵故障并随后需要将其HeartMate XVE左心室辅助装置更换为HeartMate II轴流泵的患者的记录。我们收集了关于支持时间和泵故障原因、围手术期特征及手术方式的数据。
患者使用HeartMate XVE泵平均支持473±233天。7例早期患者需要肋下和胸骨切开切口;7例后期患者仅行肋下切口。13例患者成功更换为HeartMate II;1例患者在手术室死亡。另1例患者在围手术期死亡(30天死亡率,14%[14例中的2例])。两组之间存在显著差异。仅需要肋下切口的患者手术时间较短(187分钟对220分钟;p = 0.04),需要的输血制品较少(浓缩红细胞,8.6单位对28.7单位;p = 0.03;新鲜冰冻血浆,12.4单位对30.9单位;p = 0.04)。此外,行肋下切口的患者术后重症监护病房停留时间较短(再次胸骨切开患者为5.3±1.1天对8.4±3.1天;p = 0.03)。存活患者的平均住院时间为22±14天。平均长期随访时间为11.2±7.8个月;71%(14例中的10例)患者目前存活。
通过肋下途径将HeartMate XVE更换为HeartMate II可在相对较低的发病率和死亡率情况下完成。